
GLP drugs, new technology and breakthroughs in research are transforming diabetes care — and fueling hope for a cure.

Robert A. Gabbay, MD, PhD, FACP, is chief medical officer and senior vice president at Joslin Diabetes Center and associate professor at Harvard Medical School. His research concentrates on improving health care delivery models to enhance diabetes outcomes and patients’ experiences. He is dedicated to creating a model for the patient-centered medical neighborhood for diabetes to ensure patient-centered coordinated care between the team of health professionals that are required to meet the patient’s needs. To improve quality, Dr. Gabbay has traversed many arenas, including better patient communication tools and care management, behavior change using motivational interviewing, self-management support, decision support and leveraging technology.

GLP drugs, new technology and breakthroughs in research are transforming diabetes care — and fueling hope for a cure.

The health system must rethink its strategy to enable primary care providers to develop better game plans for chronic disease patients, such as people living with type 2 diabetes.

Published: March 28th 2025 | Updated: